Q4 2025 earnings call: 15% revenue growth, $3.9M sales, CapsoCam Colon Gen 2/AI 510(k) timing, trials & funding—read now.
CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results